brensocatib bronchiectasis

News

FDA, Brensocatib and bronchiectasis

Brensocatib Becomes First FDA-Approved Therapy for Bronchiectasis

Brensocatib (Brinsupri; Insmed) gains FDA approval as the first treatment for bronchiectasis, offering hope to patients with the chronic lung disease.

Medical Dialogues · 19h

FDA Approves Brensocatib as First Treatment for Non-Cystic Fibrosis Bronchiectasis

The FDA has approved oral brensocatib (Brinsupri) for adults and children 12+ with non-cystic fibrosis bronchiectasis. As a first-in-class reversible DPP-1 inhibitor, it targets the

UPI on MSN · 2d

First drug to treat bronchiectasis lung condition approved by FDA

The U.S. Food and Drug Administration has approved Insmed's daily bronchiectasis pill, brensocatib, which will be sold under the brand name Brinsupri.

Fierce Pharma3d

Insmed’s Brinsupri scores landmark FDA nod in bronchiectasis, marking first approval of a DPP1 inhibitor

With a landmark U.S. approval Tuesday, Insmed is making waves with a new class of drug that’s also the first to be green lit in the chronic lung disease bronchiectasis. | The FDA on Tuesday signed ...

PANTHERx® Rare Selected by Insmed to Dispense BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis

PANTHERx® Rare Pharmacy, a leader in rare disease product patient access and support services in the United States, announced ...

Clinical Advisor1d

Brinsupri Approved for Non-Cystic Fibrosis Bronchiectasis

The Food and Drug Administration (FDA) has approved Brinsupri ™ (brensocatib) for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients aged 12 years and older.

Investor's Business Daily on MSN3d

Top 5% Biotech, Insmed, Hits A Record High On Its 'Skeleton Key' Approval

Insmed stock hit a record high Tuesday after the FDA approved its drug, brensocatib, for patients with a devastating lung ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results